Loading...
Market
What will be the FDA's decision on Avexitide by the end of 2024?
2
Resolution / Starting Odds
Approved for all indications • 25%
Approved for some indications • 25%
Not approved • 25%
Approval delayed • 25%
FDA official announcements
Story
Amylyx Pharmaceuticals ($AMLX) Acquires Avexitide with FDA Breakthrough Therapy Designation
Jul 10, 2024, 11:04 AM
Amylyx Pharmaceuticals ($AMLX) has announced the acquisition of Avexitide, a Phase 3-ready GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation. The acquisition aims to bolster Amylyx's portfolio in blood sugar drugs, particularly for conditions such as hyperinsulinemic hypoglycemia, including post-bariatric surgery and congenital cases. The drug has supportive p2 data. The company plans to discuss the acquisition further in an upcoming conference call. The deal is seen as advantageous due to the current biotech bear market. The acquisition involves assets from Eiger ($EIGRQ).
View original story
Similar markets
Yes • 50%
No • 50%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Approved for MASH treatment • 25%
Approved with conditions • 25%
Not approved • 25%
Decision delayed • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Approval delayed • 25%
Not approved • 25%
Yes • 50%
No • 50%
